The Center for the Genetic Engineering and Biotechnology(CIGB) developer of both drugs, stated in its Twitter account that the Surgical Hospital Hermanos Almejeiras in Havana, as in Phase I, is hosting this new research

It was stated in the same posting that at the end of the study, volunteers between 19 and 80 years of age who have not had any drug previously administered or after their convalescence, will receive results of the immune response to the natural infection and booster doses.

Mambisa, applied by means of a nasal spray, drop dispenser or a Cuban syringe device, is a unique formulation of this type based on the platform of recombinant produced antigens and a highly safe technology, according to the official information.

Abdala is the first anti-Covid 19 vaccine in the country and in Latin America, demonstrating in its phase II trial with three doses an efficacy of 92.8% against the symptomatic disease.

Read also: Emergency Use of Abdala in children between 2 and 11 years of age is authorized.

In turn, 120 subjects from the same group participated last July in the phase I clinical trial for convalescents with the same drugs.

In addition to this clinical trial, the Caribbean nation started another one the vaccine candidate Soberana Plus, from the Finlay Institute of Vaccines which also sought to evaluate the safety, reactogenicity and immunogenicity of a dose of the proposal in patients recovered from the disease.

Read here: Emergency Use of Soberana Plus vaccine approved in pediatric population between 2 and 18 years old.

The participants, in the same age group, had a history of mild, moderate or asymptomatic Covid-19 infection. In this phase I clinical trial with Soberana Plus ,the drug demonstrated the ability to produce high titles of neutralizing antibodies in convalescents.

Cubadebate with information from Prensa Latina.

Related information:

Abdala vaccine demonstrates high effectiveness in Havana against the Delta variant of SARS-COV 2.